Boehringer Ingelheim Signs ADC Deal with AimedBio; EyePoint Raises $150M
Boehringer Ingelheim, the German pharmaceutical company, has entered into a significant agreement with AimedBio to develop antibody-drug conjugates (ADCs) for cancer treatment. The deal, which was announced on March 15,…